How can the potential of the duocarmycins be unlocked for cancer therapy?
dc.contributor.author | Jukes, Zoë | |
dc.contributor.author | Morais, Goreti R. | |
dc.contributor.author | Loadman, Paul | |
dc.contributor.author | Pors, Klaus | |
dc.date.accessioned | 2021-07-06T12:22:36Z | |
dc.date.accessioned | 2021-07-21T14:39:39Z | |
dc.date.available | 2021-07-06T12:22:36Z | |
dc.date.available | 2021-07-21T14:39:39Z | |
dc.date.issued | 2021-02 | |
dc.identifier.citation | Jukes Z, Morais GR, Loadman PM and Pors K (2021) How can the potential of the duocarmycins be unlocked for cancer therapy? Drug Discovery Today. 26(2): 577-584. | en_US |
dc.identifier.uri | http://hdl.handle.net/10454/18558 | |
dc.description | no | en_US |
dc.description.abstract | The duocarmycins belong to a class of agent that has fascinated scientists for over four decades. Their exquisite potency, unique mechanism of action, and efficacy in multidrug-resistant tumour models makes them attractive to medicinal chemists and drug hunters. However, despite great advances in fine-tuning biological activity through structure-activity relationship studies (SARS), no duocarmycin-based therapeutic has reached clinical approval. In this review, we provide an overview of the most promising strategies currently used and include both tumour-targeted prodrug approaches and antibody-directed technologies. | en_US |
dc.language.iso | en | en_US |
dc.subject | Duocarmycins | en_US |
dc.subject | Cancer therapy | en_US |
dc.subject | Therapeutic agents | en_US |
dc.subject | Prodrug approaches | en_US |
dc.subject | Antibody-directed technologies | en_US |
dc.title | How can the potential of the duocarmycins be unlocked for cancer therapy? | en_US |
dc.status.refereed | yes | en_US |
dc.type | Article | en_US |
dc.type.version | No full-text in the repository | en_US |
dc.identifier.doi | https://doi.org/10.1016/j.drudis.2020.11.020 | |
dc.date.updated | 2021-07-06T11:22:38Z | |
refterms.dateFOA | 2021-07-21T14:40:10Z | |
dc.openaccess.status | Not Open Access | en_US |